A 48-Week, Randomized, Open-Label, 2-Arm Study to Compare the Efficacy of Saquinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naive HIV-1 Infected Patients (GEMINI Study)

Trial Profile

A 48-Week, Randomized, Open-Label, 2-Arm Study to Compare the Efficacy of Saquinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naive HIV-1 Infected Patients (GEMINI Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2011

At a glance

  • Drugs Saquinavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMINI
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2009 Forty-eight week results published in Journal of Acquired Immune Deficiency Syndromes, April 2009.
    • 18 Aug 2008 The trial end date is July 2008, according to Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top